series-b
Stage
1
Investors
About
TigaTx develops engineered IgA antibodies to engage neutrophils and harness their tumor-killing potential as a novel cancer immunotherapy approach.
Explore TigaTx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.